Article info

Download PDFPDF
Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)

Authors

  1. Correspondence to Dr Sergio Marin, Pharmacy Department, Hospital de Mataró, Mataró 08916, Spain; Sergiomarinrubio{at}gmail.com
View Full Text

Citation

Marin S, Pérez-Cordón L, Salvà F, et al
Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)

Publication history

  • Received November 17, 2019
  • Revised February 8, 2020
  • Accepted March 3, 2020
  • First published March 27, 2020.
Online issue publication 
November 29, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.